Beauty Brands Target ‘Ozempic Face’ Market Amid Obesity Drug Surge, ETRetail
Swiss skincare firm Galderma, Brazilian cosmetics group Natura and beauty giant L’Oreal are testing treatments for consumers worried…
AI joins the fight against superbugs
Clever Culture takes aim at superbugs AI joins the antibiotic resistance fight Faster diagnostics open a bigger opportunity…
Top 3 AI Healthcare Stocks With Revenue Growth Up To 24%
Rising global concern around AI safety at the Trump Xi summit puts a spotlight on where artificial intelligence…
Kids News: Melanoma vaccine and human brain cells powering AI just two big breakthroughs this National Science Week
Skin cancer prevention and a new “human” AI – there certainly have been some exciting new developments to…
This 7% Yielding Healthcare Powerhouse Belongs in Retirees’ Portfolios
Quick Read PFE’s 7.27% yield looks safe on a 53% adjusted payout ratio, but free cash flow fell…
The next goal for weight loss drugs? Fewer injections
For millions of people taking weight loss drugs, the next breakthrough may not be more weight loss. It…
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery cofounders Josh Meier (left) and Jack Dent Cody Pickens for Forbes L ast June, when AI…
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Investors seeking reliable dividends and healthcare exposure often find themselves choosing between AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE). Both…
This Healthcare Stock With 6%-Plus Yield: Is the Dividend Safe?
Pfizer (NYSE: PFE) is facing patent expirations for some of its biggest drugs. That’s normal for a pharmaceutical…
The Most Important Healthcare Stock You’re Not Watching
A company with a $140 billion market cap is very large. It is also highly likely to be…
Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are both pharmaceutical giants based in Denmark and the United States, respectively, with…
Johnson & Johnson Vs. Pfizer
As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify…